Toward Diagnosis of Platelet Loss in Trauma Injury Using a Microfluidic Dielectric Sensor

Maji, Debnath; Pourang, Sina; Sekhon, Ujjal Didar Singh; Gupta, Anirban Sen; Suster, Michael A.; Mohseni, Pedram

doi:10.1109/sensors43011.2019.8956491

Cited by 5 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For measurements in the MHz-frequency range, the dielectric permittivity of whole blood is sensitive to red blood cell (RBC) dynamics through the interfacial polarization of the RBC membrane and the surrounding plasma. 11,12 We have previously shown that it is the aggregation and deformation of RBCs during clot development that gives rise to changes in dielectric permittivity during blood coagulation 13,14 and that the maximum sensitivity to the blood coagulation process occurs at 1 MHz. 3 The ClotChip readout is therefore taken as the temporal variation in the real part of blood dielectric permittivity at 1 MHz (►Fig.…”

Section: Measurements Clotchip Fabrication Preanalytical Testing Anmentioning

confidence: 99%

Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background There are acute settings where assessing the anticoagulant effect of direct oral anticoagulants (DOACs) can be useful. Due to variability among routine coagulation tests, there is an unmet need for an assay that detects DOAC effects within minutes in the laboratory or at the point of care. Methods We developed a novel dielectric microsensor, termed ClotChip, and previously showed that the time to reach peak permittivity (T peak) is a sensitive parameter of coagulation function. We conducted a prospective, single-center, pilot study to determine its clinical utility at detecting DOAC anticoagulant effects in whole blood. Results We accrued 154 individuals: 50 healthy volunteers, 49 rivaroxaban patients, 47 apixaban, and 8 dabigatran patients. Blood samples underwent ClotChip measurements and plasma coagulation tests. Control mean T peak was 428 seconds (95% confidence interval [CI]: 401–455 seconds). For rivaroxaban, mean T peak was 592 seconds (95% CI: 550–634 seconds). A receiver operating characteristic curve showed that the area under the curve (AUC) predicting rivaroxaban using T peak was 0.83 (95% CI: 0.75–0.91, p < 0.01). For apixaban, mean T peak was 594 seconds (95% CI: 548–639 seconds); AUC was 0.82 (95% CI: 0.73–0.91, p < 0.01). For dabigatran, mean T peak was 894 seconds (95% CI: 701–1,086 seconds); AUC was 1 (p < 0.01). Specificity for all DOACs was 88%; sensitivity ranged from 72 to 100%. Conclusion This diagnostic study using samples from “real-world” DOAC patients supports that ClotChip exhibits high sensitivity at detecting DOAC anticoagulant effects in a disposable portable platform, using a miniscule amount of whole blood (<10 µL).

show abstract